Background: Currently available plasma cell markers include CD138 and CD38. However, CD38 is not specific to plasma cells. It is also expressed by many epithelial cells and other hematopoietic cells. In addition, rare CD138-negative PCNs may be exceedingly difficult to diagnose. MIST1 is a transcription factor expressed by mouse and human neoplastic and non-neoplastic plasma cells. Our goals were to compare MIST1 expression to CD38/CD138 in neoplasms with plasmacytic differentiation, assess reactivity in normal samples and nonplasmacytic cell lineages, and to determine whether MIST1 is expressed in CD138-negative PCNs.
M IST1 is a basic helix-loop-helix transcription factor initially described in 1997 by Lemercier et al. 1 They describe its expression in tissues with high secretory function including stomach, liver, lung, salivary gland, pancreas, and spleen. 1 MIST1 binds E-boxes within regulatory regions of genomic DNA and regulates several target genes involved in secretory vesicle trafficking and maintenance in addition to apical cytoskeletal rearrangements. [2] [3] [4] In vitro studies show expression of MIST1 mRNA to be enriched in plasma cells in response to forced expression of the transcription factor XBP1, in addition Mist1 is expressed at the transcript level in mouse plasma cells. 2, [5] [6] [7] [8] Capoccia et al 6 showed preservation of plasma cell function in MIST1-knockout mice, suggesting that MIST1 in plasma cells may be functionally redundant; however, it can be utilized as a marker of plasmacytic cell differentiation. This study showed that MIST1 was reliably expressed by normal plasma cells and by cells with plasmacytic differentiation in a small cohort of 12 PCNs. Preliminary characterization of MIST1 in plasma cells also showed reliable expression of MIST1 in plasma cells in comparison with other B cells. 6 The goal of this study is to characterize MIST1 expression through immunohistochemistry in various lymphoid neoplasms including those with plasmacytic differentiation. We hypothesize that MIST1 will be a reliable and useful marker of plasmacytic differentiation.
MATERIALS AND METHODS

Immunohistochemistry Optimization
The anti-MIST1 antibody used for immunohistochemistry in this study is a rabbit anti-human MIST1 (1:200, provided by J.M.) described previously. 3, 9 Antigen retrieval was performed with Ventana Benchmark XT (Ventana medical Systems Inc., Tuscon, AZ) cell conditioning 1 protocol in 1 mM EDTA at pH 8.0 at a primary antibody concentration of 1:400. The antibody was incubated with the tissue for 32 minutes at 371C. The counterstains used were hematoxylin II and bluing reagent. 
Patient Samples
CD138 or CD38 Expression
All cases of PCN, MZL, LPL, PB were reviewed for expression of CD38 using flow cytometry (FC500, Beckman Coulter) or for expression of CD138 through immunohistochemistry.
Monoclonal CD38 and CD138 antibodies (surface CD38 FITC PNIM0775U and CD38 PC-5 PNIM2651U, Beckman Coulter) were used in the flow cytometry assays. Prediluted commercially available mouse monoclonal CD138 (B-A38, Ventana medical Systems Inc.) was used for immunohistochemistry.
Flow cytometry was performed on the bone marrow aspirates, fresh surgical tissue (including lymph node, spleen, and other soft tissue sites), or peripheral blood. Monoclonal antibodies targeting CD38 and CD138 were used and the samples were interrogated using a Beckman Coulter FC500 flow cytometer (Beckman Coulter, Brea, CA).
Immunohistochemistry for MIST1 was performed on 86 archived paraffin-embedded patient samples representing various tissue types and lymphoid malignancy or non-neoplastic controls. Included in these are cases of plasmablastic lymphoma (PB) (10), plasma cell neoplasm (PCN) (21), follicular lymphoma (8), mantle cell lymphoma (MCL) (8), marginal zone lymphoma (MZL) (10), chronic lymphocytic lymphoma/small lymphocytic lymphoma (CLL/SLL) (9), lymphoplasmacytic lymphoma (LPL) (7) , spleen with extramedullary hematopoiesis (1), normocellular marrow without evidence of a hematopoietic malignancy (9), a CD138-negative PB (1), and a posttransplant lymphoproliferative disorder with plasmablastic differentiation (1).
RESULTS
Patient Samples
Eighty-six samples were interrogated with MIST1 immunohistochemistry. Patient demographics and diagnoses are listed in Tables 1 and 2 . Figure 1 shows a composite digital image for the various hematopoietic malignancies reacting with MIST1. In normal controls, CLL/SLL, follicular lymphoma, and MCL only scattered small plasma cells demonstrate dark nuclear reactivity with MIST1 (Q, S-U). In PCNs, there is uniform dark nuclear reactivity among plasma cells (K). In PB, it appears to be dimmer but still prominent nuclear reactivity with MIST1 (N). In MZL and LPL, a subset of the small lymphocytes is noted to show nuclear reactivity with MIST1 in addition to dark nuclear reactivity among the plasma cells (E and H). One advantage of using MIST1 immunohistochemistry in MZLs is that it highlights lymphoepithelial lesions, whereas CD138 will strongly react with both the lymphocytes and the mucosal lining epithelium making the identification of lymphoepithelial lesions difficult (I vs. H). MIST 1 is negative in the majority of lymphocytes, adipocytes, endothelial cells, and granulocytes.
DISCUSSION
This is the first study to systematically apply MIST1 immunohistochemistry to a set of B-non-Hodgkin lymphomas and PCNs to investigate the utility of MIST1 as a marker of plasmacytic differentiation. To include significant numbers of relatively infrequent malignances such as PBs, we included cases that are over 10 years old. Notably, the MIST1 antibody appears to react robustly, with continued preservation even in 10-year-old paraffin blocks.
Currently, only 2 markers of plasmacytic differentiation (CD38, CD138) are widely used clinically. CD38 is expressed by a various hematopoietic cells including bone marrow hematopoietic precursors, activated T and B cells, plasma cells, and some non-Hodgkin lymphoma most notably CLL/SLL. 10 In addition, clinical use of CD38 is primarily in flow cytometry and in frozen tissue. CD138 is more specific marker of plasmacytic differentiation, 11 however, this antigen has also been shown to be expressed by other cells such as acute myeloid leukemia, lymphoblastic leukemia, benign myeloid cells, benign and malignant plasma cells, and metastatic carcinoma. 12, 13 There are rare cases of CD38-negative and CD138negative PCNs 11, 14 in which a definitive diagnosis may be difficult, and which may be misdiagnosed as lymphomas. MIST1 may be of use in these rare cases in highlighting the malignant cells and indicating their plasma cell origin.
Our data indicate that CD138+ plasma cells coexpressed MIST1 in 100% of cases. In addition, in a rare case of CD138-negative PB, MIST1 expression was observed. This indicates that MIST1 may be a more sensitive marker of plasmacytic differentiation as compared with CD138. An interesting observation we have also made with MIST1 is that PBs tend to have weaker reactivity compared with PCNs. MIST1 helps highlight lymphoepithelial lesions in MZL and a subset of lymphocytes in addition to highlighting the plasma cells in LPL and MZL. Although some MIST1 reactivity in the adjacent gastric mucosa is present, there is a comparative difference in the intensity of MIST1 reaction allowing easier identification of lymphoepithelial lesions in some MZL that show a greater degree of plasmacytic differentiation. MIST1 reacts with normal gastric chief cells strongly, but in the setting of chronic gastritis, most epithelial MIST1 is lost. 9 Unlike CD38/CD138, MIST1 has exclusive nuclear localization; thus the pattern of reactivity is complimentary to that of cell surface markers, providing utility in in-situ analysis of plasmacytic differentiation.
Our data indicate that MIST1 is a robust and reliable marker of plasmacytic differentiation. MIST1 is useful in showing plasmacytic differentiation in CD138-negative PB. MIST1 also has utility in the diagnosis of MZL by highlighting lymphoepithelial lesions. There may also be added utility in the diagnosis of MZL and LPL in that MIST1 seems to highlight not only the plasma cells but also a subset of the lymphocytes that are presumably undergoing plasmacytic differentiation. MIST1 is also a good negative marker in other B-non-Hodgkin lymphomas such as MCL and CLL/SLL. In cases where the diagnosis of a PCN is difficult because of equivocal laboratory or radiologic findings, MIST1 can serve as additional evidence of plasmacytic differentiation. From our observations of MIST1 immunohistochemistry characteristics, it also appears that the intensity of MIST1 reaction inversely correlates with the aggressiveness of the neoplasm. However, this observation is based upon a limited number of cases and additional studies are required to establish this relationship.
In conclusion, MIST1 is a useful immunohistochemical marker of plasmacytic differentiation. MIST1 has clinical utility as a confirmatory marker in the diagnosis of lymphomas with plasmacytic differentiation, as a negative marker in other lymphoma types, and can be useful in the evaluation of difficult PCNs and lymphomas.
